Stock Markets

Stock Market News – Mylan shares are soaring after earnings at the generic drugmaker top forecasts

Mylan revenue in the quarter fell 4% to $2.86 billion from $2.99 billion a year earlier. Leading the decline were North American sales, which fell some 14% to $1.01 billion, but European sales were largely flat at $1.04 billion and the company's net sales elsewhere in the world ticked up 4% to $773.7 million.

StockMarketNews.Today


Shares of generic drugmaker Mylan N.V. shot up 14.1% on Tuesday after third-quarter profit topped analysts’ estimates. Adjusted earnings in the quarter were $1.25 a share, beating forecasts by 6 cents.

Revenue in the quarter fell 4% to $2.86 billion from $2.99 billion a year earlier. Leading the decline were North American sales, which fell some 14% to $1.01 billion, but European sales were largely flat at $1.04 billion and the company’s net sales elsewhere in the world ticked up 4% to $773.7 million.

Calling Mylan’s third-quarter health “in line” with expectations, CEO Heather Bresch touted in a statement the company’s 475 new products offered over the year. “As we look ahead, we’re very optimistic about our long-term growth prospects as we have secured almost all regulatory approvals necessary for our key 2019 product drivers around the world.” Mylan also ended the quarter with strong adjusted free cash flow at $2.02 billion for the nine months ended Sept. 30, up from $1.91 billion in 2017.



Save 50.0% on select products from ICZI with promo code 50K258CF, through 11/9 while supplies last.



Mylan Reports – Third Quarter 2018 Financial Highlights

U.S. GAAP diluted earnings per ordinary share (“U.S. GAAP EPS”) of $0.34, up 113% over the prior year period. Total revenues of $2.86 billion, down 4% compared to the prior year period and adjusted diluted earnings per ordinary share (“adjusted EPS”) of $1.25, up 14% over the prior year period.

Revenue Highlights: Rest of World segment net sales of $773.7 million, up 4%, up 11% on a constant currency basis. Europe segment net sales of $1.04 billion, flat, up 2% on a constant currency basis. North America segment net sales of $1.01 billion, down 14%, down 13% on a constant currency basis, primarily due to the combined impact of the implementation of new accounting standards, lower volumes including EpiPen® Auto-Injector sales, the divestiture of certain contract manufacturing assets, the loss of exclusivity of a product and actions associated with the restructuring and remediation program at the Morgantown manufacturing facility.



wow777

Try Amazon Prime 30-Day Free Trial



U.S. GAAP net cash provided by operating activities for the nine months ended September 30, 2018 of $1.71 billion, up 9% compared to $1.57 billion in the prior year period. Adjusted free cash flow for the nine months ended September 30, 2018 of $2.02 billion, up 6% compared to $1.91 billion in the prior year period. Mylan is not providing forward looking guidance for U.S. GAAP reported financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures. Please see “Non-GAAP Financial Measures” for additional information.



Save 40.0% on select products from Omars with promo code 40GE51G1, through 11/30 while supplies last.



Mylan CEO Heather Bresch said: “Mylan’s third quarter performance was in line with our expectations and we delivered solid year-over-year growth. Our confidence in the company’s bright future extends well beyond any single factor or particular quarter, including the current, short-term macro market turbulence our industry is experiencing. Year-to-date, we have launched nearly 475 new products across our segments, including a record number of complex generics and biosimilars for Mylan. These medicines represent many different therapeutic categories, channels and dosage forms. We remain committed to our full-year 2018 guidance, and this confirmation is not dependent on any single product approval or launch. As we look ahead, we’re very optimistic about our long-term growth prospects as we have secured almost all regulatory approvals necessary for our key 2019 product drivers around the world.”

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s